Key result
Left ventricular hypertrophy significantly shortened the time to cardiac arrest by bupivacaine in rats compared to sham controls (1,034 vs 1,302 seconds; P=0.030).
Why the study?
The impact of left ventricular hypertrophy on bupivacaine-induced cardiotoxicity and its underlying mechanisms remained undetermined.
Does left ventricular hypertrophy increase susceptibility to bupivacaine-induced cardiotoxicity in a rat model?
Does left ventricular hypertrophy increase susceptibility to bupivacaine-induced cardiotoxicity in a rat model?
Absolute Event Rate: 1034% vs 1302%
p-value: p=0.030
Left ventricular hypertrophy exacerbates bupivacaine-induced cardiotoxicity in rats, likely due to the upregulation of TRPC3 channels facilitating the entry of the anesthetic into cardiomyocytes.
May heighten bupivacaine cardiotoxicity risk in LVH via TRPC; leaves open whether channel blockade alters outcomes.
BACKGROUND: Local anesthetics, particularly potent long acting ones such as bupivacaine, can cause cardiotoxicity by inhibiting sodium ion channels; however, the impact of left ventricular hypertrophy on the cardiotoxicity and the underlying mechanisms remain undetermined. Transient receptor potential canonical (TRPC) channels are upregulated in left ventricular hypertrophy. Some transient receptor potential channel subtypes have been reported to pass relatively large cations, including protonated local anesthetics; this is known as the "pore phenomenon." The authors hypothesized that bupivacaine-induced cardiotoxicity is more severe in left ventricular hypertrophy due to upregulated TRPC channels. METHODS: The authors used a modified transverse aortic constriction model as a left ventricular hypertrophy. Cardiotoxicity caused by bupivacaine was compared between sham and aortic constriction male rats, and the underlying mechanisms were investigated by recording sodium ion channel currents and immunocytochemistry of TRPC protein in cardiomyocytes. RESULTS: The time to cardiac arrest by bupivacaine was shorter in aortic constriction rats (n =11) than in sham rats (n = 12) (mean ± SD, 1,302 ± 324 s vs. 1,034 ± 211 s; P = 0.030), regardless of its lower plasma concentration. The half-maximal inhibitory concentrations of bupivacaine toward sodium ion currents were 4.5 and 4.3 μM, which decreased to 3.9 and 2.6 μM in sham and aortic constriction rats, respectively, upon coapplication of 1-oleoyl-2-acetyl-sn-glycerol, a TRPC3 channel activator. In both groups, sodium ion currents were unaffected by QX-314, a positively charged lidocaine derivative, that hardly permeates the cell membrane, but was significantly decreased with QX-314 and 1-oleoyl-2-acetyl-sn-glycerol coapplication (sham: 79 ± 10% of control; P = 0.004; aortic constriction: 47± 27% of control; P = 0.020; n = 5 cells per group). Effects of 1-oleoyl-2-acetyl-sn-glycerol were antagonized by a specific TRPC3 channel inhibitor. CONCLUSIONS: Left ventricular hypertrophy exacerbated bupivacaine-induced cardiotoxicity, which could be a consequence of the "pore phenomenon" of TRPC3 channels upregulated in left ventricular hypertrophy.
No takes yet. Share an insight, caveat, or question.
Hino et al. (2020) studied Left ventricular hypertrophy and bupivacaine-induced cardiotoxicity (n=23). Left ventricular hypertrophy (aortic constriction) vs. Sham procedure was evaluated on Time to cardiac arrest by bupivacaine (seconds) (p=0.030). Left ventricular hypertrophy significantly shortened the time to cardiac arrest by bupivacaine in rats compared to sham controls (1,034 vs 1,302 seconds; P=0.030).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: